Peptide signalling: how short chains carry information

Signal through molecular recognition

Peptides are often described as signalling molecules because many endogenous peptide sequences transmit information between cells rather than serving primarily as structural building blocks. Their biological effect depends on molecular recognition: a peptide presents a combination of shape, charge and chemical functionality that can be recognised by a receptor or interacting protein. The same sequence may produce different effects in different experimental systems because receptor expression, downstream signalling machinery and peptide-degrading enzymes vary by cell type and tissue.

Cell-surface receptors

Most well-characterised peptide signals act at the cell surface. G-protein-coupled receptors are especially prominent, including many receptors for neuropeptides, melanocortins, growth-hormone secretagogues and other peptide ligands. Ligand binding changes receptor conformation and activates heterotrimeric G proteins, which can alter cyclic AMP, phospholipase C activity, intracellular calcium, protein kinase A or protein kinase C. Other peptide and protein ligands act through receptor tyrosine kinases, which recruit signalling complexes after phosphorylation and commonly activate PI3K/Akt and MAPK pathways.

Cytoplasmic pathways

A second group of peptide-related effects is discussed at the level of cytoplasmic signalling. Here the peptide may act through a receptor first and the measured downstream endpoint is a pathway such as AMPK, Akt, ERK, JNK or p38. Researchers use pathway inhibitors, genetic knockdown or receptor antagonists to distinguish direct pathway dependence from correlation. Without those controls, a change in phosphorylation or gene expression shows association but does not necessarily establish the molecular route.

Mitochondrial signalling

Mitochondrial peptide literature introduces another compartment. Mitochondrial-derived peptides such as Humanin and MOTS-c originate from short open reading frames within mitochondrial DNA and have been studied as stress-response signals. Synthetic mitochondria-targeted peptides such as elamipretide/SS-31 are discussed separately because they are designed to associate with mitochondrial membranes rather than being mitochondrially encoded. Published work examines oxidative stress, respiratory function, cardiolipin interactions and metabolic signalling, but much of the evidence remains model-dependent.

Proposed nuclear actions

A more controversial literature proposes direct nuclear actions for very short peptides. Work associated with the peptide-bioregulator tradition describes di-, tri- and tetrapeptides entering cells and interacting with DNA or gene-regulatory regions. Some publications report changes in transcription or telomerase-related endpoints. These mechanisms should be described as reported hypotheses or findings rather than settled general peptide biology because independent replication

is limited and the proposed direct DNA-binding model is not established to the same degree as classical receptor pharmacology.

Proteolysis and half-life

Peptide signalling is inherently time-limited because peptides are substrates for proteases and peptidases. Enzymes in plasma, extracellular fluid, endosomes and tissues can cleave peptide bonds, sometimes within minutes. Chemical modifications such as cyclisation, N-terminal protection or substitution with non-natural residues are often studied specifically because they alter proteolytic susceptibility. Measured half-life is therefore a property of a sequence in a defined biological matrix, not a universal number attached to the peptide name.

Keep analytics and pharmacology separate

For analytical work, this biology reinforces the need to separate two questions. A certificate of analysis describes what is in a vial: identity, purity and other material attributes. Signalling literature describes what a sequence has been reported to interact with in an experimental system. The existence of a receptor mechanism does not establish a human outcome, and a high-purity material does not establish biological efficacy. Technical communication is strongest when those evidence domains remain distinct and the model, receptor, endpoint and level of evidence are stated explicitly.